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The aim of this paper was to conﬁrm the eﬃcacy of adrenocorticotropin depot (ACTH-depot) therapy in pregnancies with
threatened miscarriage and preterm delivery through the desired stimulation of the adrenal glands controlled by the rest of
organism.Theactivityofhypothalamic-pituitary-adrenalaxisplaysakeyroleinpregnancy. Suchnaturallystimulatedendogenous
corticosteroid hormones are free from unwanted side eﬀects of their synthetics analogs. Low level of maternal blood ACTH and
insuﬃcient increase of induced by hypothalamic hormones oxytocinases (cystine-β-aminopeptidases) were indication to ACTH-
depot therapy (0.5mg/week) in our consecutive prospective studies. Contrary to antenatal use of synthetic corticosteroids, there
are no temporal limits of this therapy, which has to be more often recommended into clinical prevention of fetal morbidity,
treatment of premature delivery, and ﬁnally elimination of the newborn’s mortality caused by the neuroendocrinological gestoses.
1.Introduction
Hormonal therapy during pregnancy must take into con-
sideration the state of both the mother and the fetus. This
applies to the indications on the mother’s side (e.g., diabetes,
thyroid, and adrenal gland diseases) and the child’s side
(intrauterine development disorder) and to the dynamically
changing relationship between these two organisms. During
pregnancy, there is also an increase in the production
of hormones and enzymes of the placenta, the function
that has an essential meaning in the mutual mother-fetus
neuro-immunoendocrine relationship [1–4]. This applies
especially to the synthesis and concentration adjustment of
isooxytocinases (cystine-beta-aminopeptidase (CAP1)a n d
isocystine-beta-aminopeptidase (CAP2)), which decompose
hypothalamic hormones [5–7]. Any damage to the placenta
(partial separation, calciﬁcation and vascular clots), or only
hypoxia, leads to a decrease of the concentration of these
enzymes in the mother’s blood, which automatically results
in the increase of not only oxytocin and vasopressin but also
corticotropin-realising hormone (CRH) and gonadotropin-
realising hormone (GnRH), which, in consequence, pro-
vokes a change in the production of steroid hormones,
essential for the pregnancy. In 1957, Tuppy and Nesvadba
described the principles of chemical assay of the enzyme
oxytocinaseusingassubstrateL-cystine-di-β-naphthylamide
[8]. The following years brought an increasing interest in
assessment of aminopeptidase activity in obstetrics, but in
1966 Babuna and Yenen published a study on the modi-
ﬁcation of the original chemical assessment of oxytocinase
that in fact hindered investigations of enzyme monitoring in
pregnancy [9]. Three years later, these laboratory methods
were corrected, but they were published in a chemical jour-
nal, which was readily available for clinicians [10]. However,
the introductions of new methods of pregnancy monitoring
as well as divergence of opinion on the application of
oxytocinase, resulted in overshadowing of the study on
cystine-aminopeptidase activity in the pregnant women. The
oxytocinases reﬂect the state of the mother, the fetus, and
the placenta. Maternal blood levels of CAP1 and CAP2 show
high correlation with the fetal and placental mass as well
as with the fetal maturity state [11]. The constant increase
of oxytocinasemia up to the time of delivery in 81% of
pregnancies and potential stabilization of its level during
the last weeks of pregnancy in a further 12% of cases are
the most sensitive indicators of the proper development of
fetuses. In the case of the hormone deﬁcient neurosecretion
in hypothalamic nuclei and/or insuﬃciency of the placenta,2 Obstetrics and Gynecology International
thebloodleveloftheenzymeislow,itsphysiologicalincrease
is stopped, or the concentration is even lowered. In women
with hypothalamic insuﬃciency syndromes that have not
been diagnosed in time, intrauterine death of the fetus
occurs in at least 50% of cases, for which replacement
hormonal therapy with adrenocorticotropin of prolonged
activity (ACTH-depot) is successful [3, 12].
Modern techniques of monitoring and treatment of
pregnancy as a coexistence of mother and child gained a new
dimension through the individual technical quantization of
the fetal maturity process and in it the discovery of a decisive
role of two axes: hypothalamic-pituitary-adrenal axis and
hypothalamic-pituitary-gonadal axis. These axes are under
the inﬂuence of pregnancy stimuli, from the change in the
size of the uterus to the synthesis of CRH in the mother,
fetus, and the placenta, since the mechanical stimulation of
the mammary glands or the pressure of the speculum on
the vagina stimulates the production of hormones in the
hypothalamus [11, 13–16].
Medical intervention must ﬁrstly take into consideration
the natural process of gestation. When using synthetic hor-
mones, one must remember that such medications contain
an additional mixture of residual side products of their
industrial manufacture. For example, the omission of one
atom of nitrogen and hydrogen in an oxytocin molecule
doubles the increase in hormonal activity but at the same
time blocks the possibility of eﬀective action of the next
dose of thus-created desaminooxytocin. It is the exercise of
the possible action upon the receptors of dexamethason or
betamethason as the equivalent of natural cortisol that forces
the organism to actuate enzymatic defense-repair mecha-
nisms. Enzymes are of key importance for the homeostasis of
the organism and are the most sensitive clinical markers. On
the basis of the rate of change in the levels of CAP1 and CAP2
in the mother’s blood, one can determine when the death of
the fetus has occurred or—much more importantly—could
occur, or if it is in danger of miscarriage or premature birth
[11–13].
Lastly, an important role is played by the endocrine
glands themselves, in which, apart from biochemical inter-
dependencies, a signiﬁcant role is played by the biophysical
eﬀect of energy ﬂow, which one can picture as the speed of
blood ﬂow through the organs, its viscosity, the quantitative
composition of individual blood cells, and so forth. In this
conceptualization, the use of adrenocorticotropin hormone
(ACTH) leads to the desired production of corticosteroids
and their secretion by the adrenal glands but controlled in
their function by the rest of the organism [14–17].
Endogenic steroid hormones do not possess the unnatu-
ral side eﬀects of their synthetic analogs (e.g., dexamethason
or betamethason) which must, due to their prolonged eﬀect,
cause unwanted side eﬀects through blocking endogenic
production of natural corticoids. Even the administration
of natural corticoids, in pharmacological doses, not only
limits their endogenic production but also reciprocally slows
the secretion of hormones stimulating the adrenal gland,
where they originate. Similarly, apart from acting upon the
maturation of fetal lungs, these medications periodically
suppress the axis of hypothalamic-pituitaryglands [18–29].
Despite repeated and well-documented studies, no better
dosage was found than a one-time therapy between 28 and
34 weeks and twenty four hours before birth, as proposed by
Liggins and Howie [30]. It is not recommended also in cases
of multiple gestations, premature rupture of membranes
or fetal and maternal complications (i.e., resp, diabetes
hypertension, or infection) [31–33]. The mentioned factors
do not eliminate the ACTH-depot therapy, which is safe
and can be used multiply during all trimesters of pregnancy.
What is more, a correlation between serial administration of
corticotropin and the mass, maturity, and the fetal age of the
newborn has been repeatedly shown to exist. In eﬀect, this
proves the superiority of endogenic corticoids over exogenic
ones in the prevention of illness and death of the newborn
for high-risk pregnancies, while the usage of ACTH-depot,
which additionally has no time limitations as opposed to
dexamethason or betamethason. Thousands of prospectively
observed pregnancies and births showed a lowered mortality
count due to breathing disorders of the newborn, which has
been further proven through prospective studies showing
ﬁrst a lessening then a complete elimination of mortality in
cases of neuroendocrinologically induced hypertension as a
result of the pregnancy [11, 14, 34–36].
2. Indication for ACTH-Depot Therapy
Indications for the treatment of pregnant women with
adrenocorticotropin with a lengthened eﬀect (ACTH-
depot) are the following clinical diagnoses: neurohormonal
hypothalamic postpregnancy syndrome [25], habitual mis-
carriages, a premature childbirth, shortened or nonexistent
lactation after previous childbirths, and long-term usage of
anticonception pills (especially during maturation years), as
well as cytologically or colposcopically determined precan-
cerous cervical states. Special group for the treatment are
pregnant women who underwent infertility treatment, of
which 67% show clinical and laboratory indication for its
implementation [37–54].
A low concentration of ACTH in the mother’s blood
decides on the necessity of a substitution ACTH-depot
treatment. As in all hormonal examinations, the tendencies,
of a rise or fall of the level of ACTH in the blood are
essential. The fall of ACTH concentration is a natural
occurrence only before birth in pregnancies brought to
term physiologically, while at an earlier time it signals an
endangerment of the pregnancy due to a miscarriage or
premature birth. An administration of exogenic ACTH-
depot supplements deﬁciencies and counters an excessive
secretion of adrenocorticotropin-realising hormone (CRH),
and thus extends the pregnancy. Apart from determining the
level of ACTH, it is important to measure the concentration
of oxytocinases (CAP1 and CAP2), the syntheses of which
increases under the inﬂuence of a heightened secretion of
hypothalamic hormones during pregnancy.
ACTH dosage applies to intramuscular injection of
0.5mg ACTH-depot, causing a 32-hour rise in the concen-
tration of adrenal gland hormones in the mother’s blood. In
the case of an absence of normalization of the ACTH levelObstetrics and Gynecology International 3
Table 1: The results of the ﬁrst laboratory examinations of women with miscarriages and births.
Pregnancy measurement Miscarriage Birth
First Second First Second
Week of pregnancy 5,7 ± 1,4 9,06 ± 1,9∗ 6,0 ± 1,8∗ 9,1 ± 1,9
ACTH pg/ml 11,4 ± 3,02 14,1 ±5,2 12,6 ± 6,2∗ 13,0 ± 5,2
CAP1 μmol/L/min 0,61 ± 0,21 0,62 ±0,13 0,64 ± 0,17∗ 0,92 ± 0,28
CAP2 μmol/L/min 1,24 ± 0,44 1,39 ±0,18 1,40 ± 0,29∗ 1,63 ± 0,28
∗Statistically signiﬁcant diﬀerences.
in the blood and/or the persistence of clinical symptoms, the
nextdosecanbeadministeredalreadyafter48hours.Usually,
a single dose in weekly intervals during the ﬁrst trimester is
enough,withsimultaneoussubstitutionwithprogesteronein
physiological doses.
There are two types of dosage of 0.5mg ACTH-depot per
dose: (1) once a week in weekly intervals or (2) a series of
three doses every second day as long as the early pregnancy
is endangered, either by persisting nausea, morning sickness,
and pain in the abdomen or, in its later stages, by uterine
cramps and bleeding, yet always by the insuﬃcient rise of the
level of oxytocinases, or, even more so, by its decline.
The eﬀectiveness of treatment depends primarily upon
beginning the therapy as early as possible in the ﬁrst stages
of pregnancy, while the choice of dosage is decided by the
clinicaldevelopment,sincethe48-houreﬀectofasingledose
determines the need for sustaining it with a maximum of
two following doses in one series. As the pregnancy develops,
the almost immediate eﬀect (disappearance of ailment) is
sustained for an ever-increasing period of time. In the
absence of enzymatic monitoring of the pregnancy, one may
decide on the frequency of injections via the principle of
ex juvantibus. Often when beginning adrenocortical therapy,
one may refer to the case of hypothalamic insuﬃciency and
not only in women with habitual miscarriages or premature
deliveries.
Aside from enzymatic monitoring of adrenocortical
therapyastheonlymethodusedinthelast40years,currently
one may determine the ACTH level in the mother’s blood via
laboratory procedure, optimally in the morning, or at any
other daily ﬁxed time, for best comparison of the results. Of
course a level of ACTH below 5pg/ml is an indication for a
continued substitution therapy with ACTH-depot, because
the hypothalamic-pituitary-adrenal axis is more signiﬁcant
for the viability of the fetus than the hypothalamic-pituitary-
gonad axis, which was the only one taken into account until
now, especially in early pregnancy still without placental
steroidogenesis. The role of ACTH in creating a tolerance
for the embryo becomes apparent in a slight decrease in
prepregnancy level of this hormone in women with 14.1 ±
7pg/mlto12± 6pg/ml and a return to them in the second
trimester (15.4 ± 5pg/ml) to increase in the third trimester
to the highest prebirth levels of 23 ± 1pg/ml, which, in
contrast to oxytocinases, sharply decrease already during
delivery. Every quick increase of the ACTH level in an early
pregnancy indicates danger and requires a series of ACTH
doses as a complementary therapy and is usually eﬀective.
Forthatreasoninwomenwhohabituallymiscarry,anACTH
blood level of ≥20pg/ml is an exceptional indication for this
therapy, similar to women after artiﬁcial insemination with
prepregnancy levels of ≤10 pg/ml.
3. ExemplaryResultsofAdrenocorticalTherapy
Table 1 showstheresultsoftheﬁrstandsecondmeasurement
of ACTH, CAP1, and CAP2 in the sixth and ninth weeks
of pregnancies after infertility treatment in 24 pregnant
women who miscarried, as well as in 136 pregnant women
who delivered without complications, hospitalized in the
ﬁrst trimester in the period of ±3 weeks from the date of
miscarriage of each woman from the ﬁrst group. In contrast
to the statistically characteristic rise of concentration levels
of hormones and enzymes in the normal delivery group one
cannot observe this in the group of women who miscarried
[28]. The ACTH plasma concentration was assessed in whole
blood samples, collected approximately at 9 o’clock in the
morning in silicon-coated glass tubes containing EDTA as an
anticoagulant, and centrifuged immediately in a refrigerated
centrifuge. All samples were frozen at −20◦C until the
ACTH analysis was performed. Immunoassay was used to
measure ACTH (Immulite 2000 ACTH, DPC Ltd-US). The
CAP serum activity was measured by the method of Tuppy
and Nesvadba, modiﬁed by Klimek in pH 7.6 (CAP1)a n d
6.9 (CAP2)b u ﬀer using L-cystine-di-β-naphthylamide as
a substrate [3–5]. Statistical calculations were performed
using Statistica computer program (Stat Soft, Poland). The
normal distribution of values was checked by means of the
Shapiro-Wilktest.Student’st testwasappliedtocomparethe
diﬀerences between parametric data. A value of P<0.05 was
considered as signiﬁcant.
In the course of enzymatic monitoring of hormonal
treatment of subsequent pregnancies, the levels of both
CAP1 and CAP2 are lower than the initial values from
previous pregnancies. Levels of CAP1 below 0.8μmol/L/min
and CAP2 below 1.4μmol/L/min in early pregnancy under
10 weeks are an indication for beginning the therapy with
single 0.5mg doses of ACTH-depot, while levels of both
these enzymes ≤4μmol/L/min in the third trimester require
their continued use. This especially applies to laboratory-
monitored pregnancies after fertilization in vitro already
from the ﬁrst weeks of the pregnancy and not only in
those with a signiﬁcantly low level of ACTH, in which the
treatment with this hormone is the method of choice, but4 Obstetrics and Gynecology International
Table 2:ResultsoftreatmentofinfertilewomeninperiodsI(1991–1992)andII(2001–2004)withsingleandserialdosesfromthebeginning
of the pregnancy.
Group Period Serial doses Single doses Control
NNNN
Age (years) I 441 29,9 ± 5,2 140 30,2 ± 4,9 140 29,8 ± 5,1 161
II 324 29,6 ± 4,3 142 31,0 ± 4,6 100 30,0 ± 5,1 182
Number of pregnancies I3 , 2 ± 1,3 2,7 ± 1,5 2,0 ± 1,3
II 1,9 ± 1,3 2,0 ± 1,2 1,8 ± 1,3
Number of births I2 , 3 ± 1,1 1,4 ± 0,7 1,6 ± 0,8
II 1,2 ± 0,6 1,2 ± 0,6 1,4 ± 0,8
Number of miscarriages I0 , 9 ± 1,1 1,3 ± 1,4 0,4 ± 0,8
II 0,7 ± 1,0 0,8 ± 0,9 0,4 ± 0,8
Number of children I0 , 7 ± 0,8 1,2 ± 0,5 1,3 ± 0,6
II 1,2 ± 0,5 1,2 ± 0,6 1,4 ± 0,7
Number of doses I3 , 4 ± 0,6 6,0 ± 1,5 0
II 5,2 ± 2,8 9,1 ± 3,5 0
CAP1 μmol/L/min I6 , 6 ± 2,1 8,1 ± 2,3 8,8 ± 2,4
II 7,7 ± 2,5 7,8 ± 2,5 8,8 ± 2,4
CAP2 μmol/L/min I5 , 1 ± 1,5 6,6 ± 1,7 7,1 ± 1,7
II 6,4 ± 1,8 6,5 ± 1,8 6,8 ± 1,9
Length of pregnancy (days) I 262,5 ± 32 267,6 ± 11 272,5 ± 11
II 270,7 ± 22 275,0 ± 11 272,6 ± 12
Mass of newborn (g) I 2895 ± 900 3165 ± 440 3299 ± 439
II 3230 ± 504 3477 ± 420 3341 ± 480
Length of newborn (cm) I 50,5 ± 7,2 53,4 ± 2,7 54,3 ± 2,7
II 53,6 ± 3,2 55,0 ± 2,5 54,4 ± 2,6
Apgar scale points I9 , 7 ± 0,7 9,7 ± 1,6 9,5 ± 0,8
II 9,5 ± 0,8 9,7 ± 0,9 9,7 ± 1,7
Klimek scale points I9 , 8 ± 1,6 9,9 ± 1,6 10,5 ± 1,4
II 8,8 ± 1,6 8,9 ± 1,7 8,8 ± 1,7
alsointhecaseofanabsenceofaninsigniﬁcantphysiological
drop in the level of this hormone and compulsory with its
rising levels in the ﬁrst trimester instead of only in the third
[27].
Fetal maturation is a natural time-spatial process and
full-mature newborn may be small, average, or large as well
as its growth may be slow, regular, or fast. Fetal maturation
can be determined by the number of technical quanta of
maturity, just as the body weight is measured in grams,
height in centimeters and gestational age in days or weeks.
Technical quantization is based on six features of the child:
the position of the limbs, elbow angle, its mobility, breast
nipple, plantar creases, and lanugo. Each of these features
is given 2 points when fully developed or 0 points when
not developed at all. It means that immature newborns have
less than 6 points of thus-selected technical quanta. Maturity
assessed in this way immediately after the birth found a
clinical application [20–23, 53, 54]. The results of causal
ACTH-depot therapy can be demonstrated with the results
of two groups of pregnant women with a single fetus in a
10-year interval after a successful treatment of infertility, in
other words patients characterized by a shortening of their
average pregnancy duration and unfortunately doubling
the numbers of births via cesarean section. In both time
intervals (I:1991-1992 and II:2001–2004) 441 respectively
324 pregnant women were hospitalized, to be observed and
give birth under the same clinical conditions. The examina-
tion was extended to all women consecutively hospitalized
after the treatment of infertility, due to which two control
groups of 161 and 182 were created which did not receive
adrenocortical therapy [11, 13, 24, 54].
In the assessment of clinical material, it is essential to
compare both control groups, the characteristics of which
coincide as shown in Table 2 separately for both examination
periods. This data validates the results of previous studies
concerning pregnancies after a successful treatment of infer-
tility, for example, in the relation to the mean duration of the
pregnancy (272.5 and 272.6 days), average mass (aroundg),
the length of the newborn (54.3cm), their advanced fetal
maturity on the Klimek scale (index of 8.8 and 10.5), and
the postnatal adaptation on the Apgar scale (9.7 and 9.5
points). Also to be noted are the very similar levels of CAP1
and CAP2, a good sign for both the state of the enzymatic
marking methods and its diagnostic usefulness due to an
exceptional (in enzymatic examinations) repeatability of
results. The higher the concentration of CAP1 and CAP2 atObstetrics and Gynecology International 5
Table 3: Clinical characteristics of examined groups in the ﬁrst (I) and second (II) periods.
Group Period Serial doses Single doses Control
N (%) N (%) N (%)
Cervical I 43 (31%) 17 (12%) 21 (13%)
cerclage II 20 (14%) 5 (5%) 20 (11%)
Spontaneous I 116 (83%) 86 (61%) 54 (39%)
birth II 101 (71%) 82 (82%) 142 (78%)
Cesarean I 21 (13%) 63 (39%) 63 (39%)
section II 32 (23%) 25 (25%) 38 (21%)
Table 4:ComparisonofthestateofthenewbornaccordingtothereachedlevelofmaturitydependingontheuseofACTH-depotortocolysis
in the examined pregnancy.
Klimek’s maturity index 12–10 9–6 Below 6
ACTH-therapy Yes No Yes No Yes No
New-born (n (%)) 264 (80%) 89 (45%) 69 (20%) 63 (32%) 0 46 (23%)
Fetus age (days) 273 ± 10 259 ± 14 266 ± 12 231 ± 10 175 ± 17
Mass (kg) 3,4 ± 0,4 3,0 ± 0,6 3,3 ± 0,5 2,0 ± 0,5 1,2 ± 0,3
Maturity (points) 11,4 ± 0,7 11,0 ± 0,5 8,2 ± 0,9 8,0 ± 1,0 4,0 ± 1,0
Apgar adaptation 9,6 ± 0,8 10,0 ± 1,0 9,4 ± 0,8 8,0 ± 1,0 5,0 ± 2,0
Oxytocinase (μmol/L/min) 7,8 ± 2,8 3,0 ± 0,7 8,1 ± 3,4 3,0 ± 1,0 3,0 ± 1,0
the end of the pregnancy, the higher the neurosecretive and
immunological capacity of the mother. This is conﬁrmed by
the juxtaposition of prenatal levels of these enzymes together
with the corresponding increase in fetal age, mass, length,
maturity, and the postnatal adaptation of the infant to the
values characterizing the infants of the control groups which
did not need a substitutive adrenocortical therapy.
Compared to patients of the control groups not in need
of this therapy, the patients who were treated hormonally
(with the same number of births) diﬀered only in having
twice the number of miscarriages (0.87 ± 0.56:0.4 ± 0.8,
P<0.001). The application of single doses once a week
extends the length of a pregnancy by an average of 8 days
and increases the mass by 450g and the length of the infant
by 4cm. The increase of the total number of doses from 4
(range 3–6) to 6 (range 1–19) causes an increase in the levels
of oxytocinases in the last month of the pregnancy.
After ten years, the percentage of spontaneously initiated
births in the control group has doubled from 39% to 78%
with a simultaneous fall of the percentage of cesarean section
from 39% to 21%, with an almost unchanged necessity of
adding a cervical cerclage, namely 13% to 11% (Table 3).
A slightly increased number of doses of ACTH-depot,
respectively, from roughly 3.4 to 5.2 and 6.0 to 9.1 led to
a halved number of cervical cerclages (from 31% to 14%
and from 12% to 5%), while the number of spontaneously
initiated births and cesarean section resembled control
group.
The application of ACTH-depot results in the disap-
pearance of symptoms of a premature birth without the
need for tocolysis and leads to the decrease of breathing dis
orders in infants. Klimek’s maturity index shows a high
positive correlation with fetus age, mass, and the length of
the infant, while its limit value of six points statistically dif
ferentiates the maturity of the fetus [50]. Table 4 shows a
comparison between the state of the newborn of same fetal
maturity when the endangered pregnancy was treated with
either ACTH-depot or tocolysis. The use of ACTH-depot
statistically lengthens the pregnancy time by 14 days and
increasesthebodymassby400gin264fullymaturenewborn
infants (10–12 K points) while in 69 less mature children (6–
12 K points) the pregnancy time extension is 35 days and
the mass increases by 1300g. It also eliminates premature
delivery in 209 pregnant women with tocolysis where in
46 (23%) of them premature birth has been identiﬁed. A
low prenatal concentration of oxytocinases on the order of
3 ± 1μmol/L/min unambiguously points to an insuﬃciency
in the production of neurohormones. A substitutive therapy
with ACTH-depot causes a normalization of the prenatal
concentration of oxytocinases (7.8 and 8.1μmol/L/min).
4. Conclusion
The pregnant patients in need of substitution therapy with
a clinical endangered pregnancy miscarried in a whole 80%
of cases before the introduction of ACTH-depot therapy
in obstetrics 40 years ago [1, 6, 25]. The best results are
obtained in habitual miscarriages due to the hypothalamic
insuﬃciency of the mothers because the damage to the
neurosecretory brain cells is permanent, and only the sub-
stitutive administration of ACTH is an eﬀective procedure.
Every patient should be informed about this, whether their
pregnancy ended with a successful birth or a miscarriage.
After giving birth in a pregnancy treated with the help of
ACTH-depot, many patients mistakenly consider themselves
as permanently cured of infertility.6 Obstetrics and Gynecology International
ACTH-therapy is decisive in high-risk pregnancies, espe-
cially so in multifetal ones. The eﬀectiveness of an enzymat
icallymonitoredtherapyfromthe25thweekofpregnancyon
is dependant in large measure on monitoring the maturity
level of each fetus separately. In the case of an uneven rate
of growth even when the levels of both CAP1 and CAP2 are
correct, it is indicated to increase the frequency of ACTH-
depot dosage.
Pregnant women who received only single doses of the
ACTH-therapy for the entire duration of pregnancy had
statistically signiﬁcant longer gestation and higher newborn
mass and length than patients who received a series of three
hormonal injections.
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